---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-26-000040"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2026-08-05T10:27:37+00:00"
generated_at: "2026-08-05T10:30:06.185666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Elanco Q2 revenue up 10% to $1.37B; raises full-year guidance on innovation momentum

## Summary
- Q2 revenue $1,368M (+10% YoY); organic constant currency growth 8%.
- Adjusted EPS $0.34 (+31% YoY); reported EPS $0.11 vs $0.02.
- Full-year 2026 guidance raised: revenue $5.09B-$5.14B, Adj EBITDA $1.01B-$1.035B, Adj EPS $1.10-$1.16.
- Innovation revenue target raised to $1.25B; net leverage ratio improved to 3.1x, targeting ~3.0x year-end.
- Pet Health revenue +12% driven by Zenrelia and Credelio Quattro; Farm Animal +9%.

## SEC filing metadata
- accession: 0001739104-26-000040
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2026-08-05T10:27:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/0001739104-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elan-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-26-000040
- JSON: https://secwatch.observer/filing/0001739104-26-000040.json
- Plain text: https://secwatch.observer/filing/0001739104-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.